This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Array BioPharma (ARRY) Up 27.1% Since Last Earnings Report?
by Zacks Equity Research
Array BioPharma (ARRY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Array BioPharma Inc. (ARRY) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Array BioPharma Inc. (ARRY).
Array BioPharma Gains on Colorectal Cancer Study Success
by Zacks Equity Research
Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.
All You Need to Know About Array BioPharma (ARRY) Rating Upgrade to Buy
by Zacks Equity Research
Array BioPharma (ARRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates
by Zacks Equity Research
Array BioPharma's (ARRY) top and bottom lines beat estimates in the third quarter of fiscal 2019. Momentum in uptake of Braftovi-Mektovi combination therapy continues.
Array BioPharma (ARRY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Array BioPharma (ARRY) delivered earnings and revenue surprises of 19.05% and 25.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up
by Zacks Equity Research
Zoetis (ZTS) exceeds both earnings and sales expectations in the fourth quarter of 2018.
Will Array BioPharma Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Array BioPharma.
Array BioPharma (ARRY) Soars: Stock Adds 11% in Session
by Zacks Equity Research
Array BioPharma (ARRY) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Here's Why Array BioPharma (ARRY) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Array BioPharma (ARRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Array BioPharma (ARRY) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Array BioPharma (ARRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Array BioPharma (ARRY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Array BioPharma (ARRY) delivered earnings and revenue surprises of 68.75% and 68.41%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Array BioPharma (ARRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Array BioPharma (ARRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has Array BioPharma (ARRY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ARRY) Outperforming Other Medical Stocks This Year?
Moving Average Crossover Alert: Array BioPharma
by Zacks Equity Research
Array BioPharma Inc. (ARRY) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
What Makes Array BioPharma (ARRY) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Array BioPharma (ARRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Incyte (INCY) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Incyte (INCY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Array BioPharma (ARRY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Array BioPharma (ARRY) delivered earnings and revenue surprises of 42.86% and 59.55%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Array BioPharma (ARRY) Q1 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Array BioPharma (ARRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Array BioPharma (ARRY) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Array BioPharma (ARRY) delivered earnings and revenue surprises of 0.00% and -3.11%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
by Zacks Equity Research
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
Array BioPharma (ARRY) Looks Good: Stock Adds 5.2% in Session
by Zacks Equity Research
Array BioPharma (ARRY) shares rose more than 5% in the last trading session, amid huge volumes.
Key FDA Events in June Investors Need to Watch Out For
by Zacks Equity Research
Investors in the healthcare industry are likely to keep a watch on upcoming PDUFA dates for key drugs in Jun 2018.
Array BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Array BioPharma (ARRY) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.